West Pharmaceutical Services, Inc. (WST)
Last Price$228.1(1.8%)
Market Cap$16.9B
WST Rating
WST Quality rating performance
WST Intrinsic Value
Key Highlights:
As of Mar 03, 2025 WST Relative Value is $206.4, which is overvalued by 9.5%, compared to current share price of $228.1.
As of Mar 03, 2025 WST DCF Value is $103.0, which is overvalued by 54.8%, compared to current share price of $228.1.
WST Share Price History
1W 3.2%
1M (32.3%)
6M (25.0%)
YTD (34.4%)
1Y (36.3%)
3Y (41.3%)
5Y 49.8%
10Y 334.8%
Share Price
Intrinsic Value
Drawdown
Total Return
vs SP500
vs NASDAQ
Crunching data... Almost there!
WST Stock Metrics
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
Base
$16.9B
$16.7B
$2,893.1M
$276.4M
Shares Outstanding
74M
Employees
11K
Growth (CAGR)
9.5%
14.1%
15.56%
10.67%
Profitability
34.6%
19.9%
17.0%
22.6%
9.6%
56.1%
Intrinsic Value
$152.8 (33.0% overvalued)
$102.8
$202.9
$102.2
21.8%
Return on Capital
Financial Health
($182.3M)
(0.7x)
191.5x
11.3%
Dividends
6.2%
0.3%
21.4%
Nov 13, 2024
Earnings
Apr 23, 2025
BEAT by 5.0%
BEAT by 18.9%
8 Beat & 2 Miss
WST Stock Financials
WST Income Statement Metrics
Annual
Quarterly
LTM
WST Cash Flow Statement Metrics
Annual
Quarterly
LTM
Operating Cash Flow (OCF)
$653.4M -15.9% YoY
Capital Expenditure (CAPEX)
($377.0M) +4.1% YoY
Free Cash Flow (FCF)
$276.4M -33.3% YoY
WST Income Statement Overview
Annual
Quarterly
LTM
Dec'15
Dec'16
Dec'17
Dec'18
Dec'19
Dec'20
Dec'21
Dec'22
Dec'23
Dec'24
$2,893.2M (1.9%) YoY
Cost of revenue
$1,894.7M 4.1% YoY
Pre-tax income
$585.5M (16.1%) YoY
20.2% margin
WST Balance Sheet Overview
Annual
Quarterly
LTM
Dec'15
Dec'16
Dec'17
Dec'18
Dec'19
Dec'20
Dec'21
Dec'22
Dec'23
Dec'24
Assets
Liabilities
Total assets
$3,643.4M
Current assets ($1,538.1M, 42.2% of total)
$484.6M (13.3%)
$552.5M (15.2%)
Other current assets
$501.0M (13.8%)
Non-current assets ($2,105.3M, 57.8% of total)
$202.1M (5.5%)
$1,686.1M (46.3%)
$10.8M (0.3%)
Other non-current assets
$206.3M (5.7%)
Financial position
($182.3M)
Cash & Short-term
Investments
Total Debt
WST Stock Ratios
Annual
Quarterly
LTM
Industry Median
5Y Historical Average
Benchmark
WST Earnings Surprises
Crunching data... Almost there!
WST Dividends
WST Dividend Yield
Crunching data... Almost there!
WST Dividend Per Share
3Y
10Y
30Y
Annual
Quarterly
LTM
Competing with WST
Overview
Ratings
Intrinsic Value
Valuation
Growth
Profitability
Health
Capital allocation
Momentum
Earnings
Dividends
Company name | Market Cap | Quality rating | Intrinsic value | 1Y Return | Revenue | Free Cash Flow | Revenue growth | FCF margin | Gross margin | ROIC | Total Debt to Equity |
$16.9B | 6.1 | $152.8 33.0% overvalued | (36.3%) | $2,893.1M | $276.4M | (1.9%) | 9.6% | 34.6% | 18.6% | 11.3% | |
$207.3B | 6.9 | $106.1 81.3% overvalued | 41.5% | $8,352.1M | $1,077.2M | 17.2% | 12.9% | 67.5% | 26.8% | 0.0% | |
$66.3B | 6.1 | $262.7 15.0% undervalued | (1.4%) | $20.6B | $2,936.0M | 5.9% | 14.2% | 59.4% | 5.4% | 55.9% | |
$46.6B | 6.4 | $81.3 13.6% overvalued | 9.9% | $9,926.1M | $608.0M | 3.6% | 6.1% | 55.6% | 9.1% | 23.8% | |
$34.6B | 7.6 | $190.6 18.2% overvalued | 29.9% | $4,926.8M | $1,388.4M | 12.9% | 28.2% | 57.9% | 32.9% | 16.0% | |
$18.6B | 5.8 | $92.7 1.2% undervalued | (10.8%) | $3,895.4M | $288.1M | 8.4% | 7.4% | 62.8% | 5.9% | 32.0% | |
$17.9B | 4.7 | $52.7 51.1% undervalued | (16.2%) | $12.9B | $566.0M | (14.0%) | 4.4% | 37.1% | (1.5%) | 191.5% | |
$14.7B | 7.3 | $131.7 108.2% undervalued | (15.2%) | $4,038.9M | $1,135.5M | 1.8% | 28.1% | 56.2% | 13.2% | 1.0% | |
$10.4B | 5.2 | $139.9 26.6% overvalued | 50.3% | $2,094.4M | $145.3M | 2.3% | 6.9% | 48.0% | (14.8%) | 69.2% | |
$9,757.8M | 6.5 | $174.5 19.0% undervalued | 4.2% | $3,582.9M | $349.2M | 2.7% | 9.7% | 48.7% | 12.0% | 27.7% | |
$8,979.7M | 5.9 | $29.8 80.8% overvalued | (20.6%) | $616.0M | $131.3M | (8.0%) | 21.3% | 46.9% | (1.2%) | 33.3% |
FAQ
What is West Pharmaceutical Services, Inc. (WST) stock rating?
As of today, West Pharmaceutical Services, Inc. has a stock rating of 6 (out of 10), which is considered Good.
is West Pharmaceutical Services, Inc. (WST) a good stock to buy?
As of today, West Pharmaceutical Services, Inc. has a Good stock rating, which is 33.0% overvalued. According to Value Sense backtesting, stocks with similar profile tend to underperform the market by 4.6%.